N/A
N=195
The PRISM Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer
Cancer · Quality of Life · Anxiety · Depression · Hope
Bottom Line
View on ClinicalTrials.gov: NCT03668223 ↗Enrolled (actual)
195
Serious AEs
0.0%
Results posted
Oct 2024
Primary outcome: Primary: Pediatric Quality of Life Cancer Module — 66.89; 68.41 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Promoting Resilience in Stress Management (PRISM) (Behavioral)
- Age
- Pediatric, Adult · 12+ yrs
- Sex
- All
- Sponsor
- Dana-Farber Cancer Institute
- Primary completion
- Jan 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pediatric Quality of Life Cancer Module |
66.89; 68.41 | — |
| SECONDARY Hospital Anxiety and Depression Scale (HADS) Total Score |
8.27; 9.94 | — |
| SECONDARY Snyder Hope Scale |
48.06; 46.89 | — |
| SECONDARY Connor Davidson Resilience Scale |
28.05; 27.45 | — |
Summary
Multi-Site Randomized Controlled Trial testing the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention among Adolescents and Young Adults with Advanced Cancer
Eligibility Criteria
Inclusion Criteria
- Age 12-24 years
- Diagnosed with advanced cancer: progressive, recurrent, refractory disease or any diagnosis with estimated overall survival <50% at least 2 weeks prior to enrollment
- Able to speak English
- Able to read English or Spanish
- Cognitively able to participate in interviews
Exclusion Criteria
- Patient Refusal
- Parent Refusal (if patient <18 years-old)
Data sourced from ClinicalTrials.gov (NCT03668223). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.